LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$76.13 USD
+0.13 (0.17%)
Updated May 10, 2024 04:00 PM ET
After-Market: $76.12 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 121 - 140 ( 189 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Biologics Strength, Cost Containment Drive 2Q Beat and Raise
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Light 4Q Offset by Solid 2017 Outlook; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Updating Model for Restore Flow Allografts Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Record 3Q on Accelerated Sales Growth and Notable Margin Expansion; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
2Q Beat and Raise; Baxter Disruption is a New Tailwind
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Solid 1Q; ProCol Acquisition Leads to Increased 2016 Growth Outlook
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
ProCol Acquisition - Small but Synergistic Biologic Tuck-In
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
4Q Record Sales, EBITDA, EPS; 2016 Guide Above Expectations; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Proposed Tax Bill to Suspend Medical Device Excise Tax
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C